14 months in and dose escalation is still the thing I get wrong
I have had 12 orders now and I keep a table, so here is the honest summary rather than a vibe.
Material has been consistent. Communication has not. Shipping has varied by about 4 days on nominally the same lane, which matters more in summer than in February.
The independent number came back 96.8% against a claimed 99.1%, which I read as agreement rather than a discrepancy — inter-lab variance on this assay is a point or two either way and treating one lab as ground truth is how people end up in pointless arguments with vendors.
Batch number is in the comments. Ask if you want the method.
best — the order this archive was captured in
Inter-lab variance on this kind of assay is routinely 1–2 points. Different column, different gradient, different integration.
retatrutide is not approved anywhere for human use, posts must not read as instructions
the weight curves are unusually steep, which makes predicting individual response harder
nobody should be giving this to anyone without extensive monitoring
This is the "correlation is mechanism" thing again. You changed three variables at once.
Water content matters more than people think. If a vial is carrying residual moisture, your "10mg" is not 10mg of peptide.
Water content matters more than people think.
Adding to this: triple agonist is doing more work than the comment implies.
Dose escalation on retatrutide is steeper and faster than on semaglutide. Do not assume the titration patterns transfer.
The glucagon component does different things than dual agonism. The constipation are not just amplified versions.
Yeah, phase 2 retatrutide is interesting but it is not comparable to phase 3 compounds.
- 1Inter-lab variance on this kind of assay is routinely 1–2 points. Different…5 comments in this branch · started by u/discount_math_dm
- 2Water content matters more than people think. If a vial is carrying residual…5 comments in this branch · started by u/ismael_eriksen